Cargando…
Phase I–II study of plitidepsin and dacarbazine as first-line therapy for advanced melanoma
BACKGROUND: This phase I–II trial compared plitidepsin 1-h infusion alone or combined with dacarbazine (DTIC) 1-h infusion as front-line therapy for advanced melanoma. METHODS: The recommended dose (RD) for plitidepsin/DTIC was defined in the first stage. In the second stage, patients were randomise...
Autores principales: | Plummer, R, Lorigan, P, Brown, E, Zaucha, R, Moiseyenko, V, Demidov, L, Soriano, V, Chmielowska, E, Andrés, R, Kudryavtseva, G, Kahatt, C, Szyldergemajn, S, Extremera, S, de Miguel, B, Cullell-Young, M, Calvert, H |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3776988/ https://www.ncbi.nlm.nih.gov/pubmed/23989947 http://dx.doi.org/10.1038/bjc.2013.477 |
Ejemplares similares
-
Plitidepsin Has a Safe Cardiac Profile: A Comprehensive Analysis
por: Soto-Matos, Arturo, et al.
Publicado: (2011) -
Phase II Study of Biweekly Plitidepsin as Second-Line Therapy for Advanced or Metastatic Transitional Cell Carcinoma of the Urothelium
por: Dumez, Herlinde, et al.
Publicado: (2009) -
A randomized phase III study comparing dacarbazine, BCNU, cisplatin and tamoxifen with dacarbazine and interferon in advanced melanoma
por: Middleton, M R, et al.
Publicado: (2000) -
Sorafenib and dacarbazine as first-line therapy for advanced melanoma: phase I and open-label phase II studies
por: Eisen, T, et al.
Publicado: (2011) -
Plitidepsin for multiple myeloma
Publicado: (2019)